PhaseV Validates GLP-1 Adverse Event Model on Patient Data
Oct 14, 2026
Healthcare
PrecisionLife and Ovation to Launch GLP-1 DNA Test by 2026
Apr 15, 2026
PrecisionLife and Ovation.io have agreed to co-develop laboratory tests and a consumer DNA test to predict individual responses to GLP-1 drugs, with commercial launch planned for the second half of 2026.
PrecisionLife and Ovation.io have entered into a collaboration to develop laboratory and consumer genetic tests focused on GLP-1 drug response, announced in a press release. The companies aim to launch a consumer DNA test in the second half of 2026 to help individuals understand their likely safety, efficacy, and tolerability profiles for GLP-1 receptor agonist therapies.
The collaboration builds on PrecisionLife’s analysis of Ovation’s GLP-1 dataset, which identified distinct biomarkers for glycemic control and weight loss. These findings will be validated across additional datasets over the next six months, including studies on semaglutide and tirzepatide. The partners plan to use these insights to support clinical trials and inform reimbursement decisions for payors.
The companies also intend to co-develop laboratory developed tests (LDTs) for use in clinical trials to identify strong responders in new therapeutic areas. Discussions with pharmaceutical partners are underway to integrate these stratification tools into drug development and post-marketing studies.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Enterprise
Nov 13 ETR survey: Claude leads enterprise AI tools on satisfaction and spending plans Nov 13 Peter Sarlin's PostScriptum takes majority stake in Finnish AI deployment firm Brillian Nov 13 Gondola says Codex lifted engineering output 25% as revenue more than doubled Nov 13 DuPont teams with Microsoft and NobleAI to speed up R&D with AI Nov 13 Korean AI startups fear Huang exit could delay planned NVIDIA investmentsMore from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
.png)
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
Illumina Adds Three Research Tools to BioInsight Platform
Oct 21, 2026
Scientific Research
Orakl Oncology Raises $34 Million to Predict Cancer Drug Response With AI
Nov 12, 2026
Funding
Boehringer Ingelheim and Microsoft to Study Digital Patient Twins
Oct 23, 2026
Life Sciences
CPG Radar rolls out Signals and LeadLogic for product research and sales
Oct 15, 2026
Marketing AI
Zealand Pharma signs AI obesity drug deal worth up to $1.2 billion
Oct 15, 2026
Biotech
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.